Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 19/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710464 | 1.00 | SMYD3 (1.00) | SMYD3LCKCSF1RKDRMAPK14 | |
| SCHEMBL28148124 | 0.88 | SMYD3 (0.87) | SMYD3LCKCSF1RKDRMAPK14 | |
| SCHEMBL21490065 | 0.84 | SMYD3 (1.00) | SMYD3LCKCSF1RKDRMAPK14 | |
| SCHEMBL19710016 | 0.84 | SMYD3 (1.00) | SMYD3LCKCSF1RKDRMAPK14 | |
| SCHEMBL21490116 | 0.81 | SMYD3 (0.70) | SMYD3 | |
| SCHEMBL19710282 | 0.81 | SMYD3 (0.70) | SMYD3 | |
| SCHEMBL23575942 | 0.81 | SMYD3 (0.67) | SMYD3 | |
| SCHEMBL19710283 | 0.81 | SMYD3 (0.67) | SMYD3 | |
| SCHEMBL21489994 | 0.81 | SMYD3 (1.00) | SMYD3 | |
| SCHEMBL19710314 | 0.81 | SMYD3 (1.00) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885LCK 2091/4885CSF1R 4038/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885LCK 1429/4885CSF1R 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.